Mito Health is best when you want to browse a large marker menu and price-compare nearby labs before you book. AMORTAL is different — it isn't a lab. It takes whatever results you bring and turns them into one ranked next action, a watchlist, a clinician-ready question, and a loop that checks whether the action actually worked.
Mito Health is built for access and price discovery: you choose what to test, browse a large marker menu, compare lab pricing, book a draw at a nearby lab, and receive clinician-reviewed next steps. It answers the question “what can I test, and what will it cost?” very well.
It is deliberately not built to answer the next question — “out of a thousand-plus options, which markers are actually worth booking, and what should the results change?” That’s the gap this page is about. A giant menu makes it easy to test broadly and chase every slightly-off number. Below is a fair, source-backed look at what Mito is excellent for, and where AMORTAL fits as the decision layer on top. It’s educational, not medical advice.
+
Use Mito to price-shop the lab. Use AMORTAL to decide which markers are worth booking, what to ignore, what to watch, and when to retest.
The short version: who each is for
These two aren’t really competitors — one is the marketplace, the other decides what’s worth booking and what each result should change. Here’s the honest split.
Which one fits which job
Mito HealthBest for marker breadth + price discoveryA pick-your-own lab marketplace — choose from a large marker menu (Mito advertises 1,000+ markers), compare prices, and book a draw at a nearby lab. Strongest when you want direct access and want to shop the cost of a test before you commit.
AMORTALBest for deciding what to do nextNot a lab. A longitudinal decision layer that reads whatever results you already have — from Mito or anywhere — and returns one ranked next action, a watchlist, a clinician-ready question, and an outcome loop. Including when to do nothing.
This isn't an "A beats B." Mito answers what can I test, and for how much; AMORTAL answers which of it is worth it, and what should it change. The strongest setup uses both.
Mito Health vs AMORTAL, at a glance
Tap between the two to see what each is actually responsible for.
What each one owns
Same goal — better decisions from your blood — split into the access-and-price job and the decision job.
The marketplace layer
Mito lets you choose what to test, browse a large marker menu (Mito advertises 1,000+ markers), compare lab prices, book a draw at a nearby lab, and receive clinician-reviewed next steps.
You want direct access to a wide marker menu and want to price-compare a test before you book. Verify the current marker count, lab prices and partner labs before you buy.
The decision layer
AMORTAL doesn't draw blood or sell tests. It takes your Mito results (or any lab's), normalises them into a memory, and produces one ranked next action, a watchlist, a clinician-ready question, and an outcome loop — with restraint built in.
You're staring at a 1,000-plus menu and the real question is "which of these is worth it?" — what to book, what to ignore, what to watch, and when a retest is actually worth it.
AMORTAL has no direct Mito integration — you bring the data in by upload or manual entry.
The comparison, row by row
| Dimension | Mito Health | AMORTAL |
|---|---|---|
| Best use case | Browse a large marker menu and price-compare labs | Deciding what the data should change |
| Collection method | Blood draw at a nearby booked lab (as advertised) | No draws — works from results you already have |
| Lab partner / processing | Multiple labs, price-compared (as advertised) | Lab-agnostic; vendor-neutral by design |
| Biomarker breadth | Very large menu (Mito advertises 1,000+; verify) | Doesn’t test; reads whatever you bring |
| Upload existing labs | Marketplace — you pick tests to book | Yes — bring Mito or any other results in |
| Wearable integration | Not the core product | Connects labs to Oura / Whoop / Apple Watch context |
| Clinician review | Clinician-reviewed next steps (as advertised) | Clinician-compatible questions; not a clinician |
| Action plan depth | Next steps (as advertised) | One ranked next best action, plus restraint |
| Retesting cadence | Pay-per-test, your own cadence | Tells you when not to retest yet |
| Result trend tracking | Trends across tests you book | Longitudinal memory across providers and time |
| Abnormal-result handling | Clinician-reviewed next steps (as advertised) | Safety-gated; routes urgent flags to a clinician, never diagnoses |
| Data portability | Your results live in Mito | Cross-provider memory you carry with you |
| Cost model | Price-compared pay-per-test (verify) | Decision layer — founding membership |
| Where AMORTAL fits | Marker menu + price in | → ranked decision, watchlist, and outcome loop out |
Provider rows describe what Mito publicly advertises as of June 2026 — pricing, marker count and partner labs change often, so confirm the current details on Mito's own pages before buying. Sources are listed at the foot of this page.
Which one fits what you actually want
| What you want | Reach for |
|---|---|
| To browse a huge marker menu and compare lab prices | Mito Health |
| To book a nearby lab cheaply | Mito Health |
| I already have results — tell me what to do next | AMORTAL |
| To not chase every marker in a 1,000+ menu | AMORTAL |
| To rank one next step that’s actually worth it | AMORTAL |
| To know whether a change actually worked | AMORTAL (then retest via Mito) |
| To know whether I should retest yet | AMORTAL |
| To connect a blood result to my wearable trends | AMORTAL |
How AMORTAL complements Mito Health
The model is simple: let Mito handle access and price discovery, then run the result through a decision process instead of a dashboard.
- Bring the result in. Upload your Mito report or enter the key markers — there's no direct integration, so you carry the data over.
- Normalise into memory. AMORTAL files each biomarker into a longitudinal record, not a one-off screen.
- Connect the context. Results are linked to your goals, symptoms, wearables, medications and constraints.
- Activate the standards. The guidelines and decision rules that actually apply to your situation switch on.
- Produce a Decision Contract. One change at a time, with the expected signal and the window written down in advance.
- Rank one Next Best Action. Not ten. The single highest-value move — which may be "do nothing yet."
- Set the watchlist. Markers worth re-checking get an expected direction and a recheck window.
- Close the loop. When your next Mito test or outcome signal arrives, AMORTAL checks whether the action worked — and keeps or discards it.
A decision loop, end to end
Here’s the same flow on a single example — illustrative numbers only, not a target or a reference range.
From a Mito result to a tracked outcome
You price-shop Mito, book one lipid marker, and it returns an elevated value your clinician flags as worth attention. On a marketplace, that's a red number and a nudge to book more.
AMORTAL files it next to your prior lipids, your goals, your current medications and your wearable trends — so it's read as a trajectory, not a single dot.
One lever, not five. The expected signal and the window to see it are written down before anything changes — and before you add ten more markers to the cart.
Framed as a clinician-ready question — "given this trend, is [one specific lever] the right first move?" — not a treatment directive AMORTAL has no authority to give.
The marker goes on watch with an expected direction and a recheck window — so you retest when it's informative, not because a draw is cheap.
Next time you book that marker on Mito, AMORTAL checks: did it move as expected? If yes, the change earns its place. If not, it's dropped — no story told over noise.
AMORTAL doesn't diagnose and isn't a substitute for your clinician — anything urgent goes to a professional, now.
A menu of 1,000+ markers — should you book this one?
Access isn’t a reason to test. Walk a single marker through this before you add it to the cart.
1,000+ markers available — test this one?
Would this marker change a decision you'd actually make?
Is this a one-off curiosity, or part of tracking something specific?
Do you already have a recent value for it?
Access isn't a reason to test. A marker that wouldn't change anything you'd actually do is a cost, not a signal — leave it on the menu until that changes.
Curiosity is fine, but price it against what you'd do with the answer. If a result wouldn't move a real decision, the cheapest test is still too expensive. Note it and move on.
You already have a recent value, so a fresh draw mostly buys you noise. Wait for a meaningful window — a lower price isn't a reason to retest early. AMORTAL sets that window so you book when it's informative.
This is a fair one to book. Set the expected signal and the window before you draw — that's a Decision Contract, and it's what turns a slightly-off number into a result you can read.
Where Mito is strongest — and where it isn’t
In fairness to both tools:
- Mito is strongest when you want direct access to a wide marker menu and want to compare lab prices before you book a draw.
- Mito may be less ideal if your bottleneck isn’t getting access but deciding which of a thousand markers is worth booking, or if a big menu tempts you to test broadly and chase every borderline number.
- Verify before you buy. Marker count, lab prices, partner labs and clinician-review language all change — confirm the current details on Mito’s own pages.
- A booked marker is a beginning, not an answer. Some results will need a clinician; AMORTAL should never be read as a diagnosis.
Bring your results into a decision, not a dashboard
AMORTAL doesn’t need to be where you shop for every blood test. The stronger model is to let a marketplace like Mito handle access and price discovery, then use AMORTAL as the longitudinal decision system around those results. Upload a Mito report, or enter the markers that matter. AMORTAL turns the result into memory, evaluates what’s still missing, ranks the next best action, sets a watchlist for the signals to expect, and later checks whether the action actually worked.
Already have results from Mito Health? Bring them into AMORTAL and ask the only question that matters: “What should I do next?”
Sources
Provider claims describe what each company publicly advertised when this page was last fact-checked (26 June 2026). Pricing, marker counts and partner labs are volatile — verify on the official pages before purchase.
Mito Health — pick-your-own tests, the marker menu, lab price comparison, and clinician-reviewed next steps.
Educational only — this is not medical advice or a diagnosis. Talk to a licensed clinician about your own numbers, targets, and any treatment decisions.
Frequently asked
Can I use AMORTAL with my Mito Health results?
Yes — that's the intended use. Mito lets you pick tests, book a nearby lab, and get clinician-reviewed next steps; you bring those results into AMORTAL by uploading the report or entering the key markers. AMORTAL normalises them into a longitudinal memory, connects them to your goals, wearables and any protocols, and returns one ranked next action rather than a long menu of numbers. AMORTAL has no direct Mito integration; you bring the data in.
Does AMORTAL replace Mito Health?
No. They do different jobs. Mito is a marketplace and data source — you choose what to test, compare lab prices, and book the draw. AMORTAL is a decision layer that sits on top of whatever lab data you have. Most people who use both keep Mito for access and price discovery, and use AMORTAL to decide which markers are worth booking, what each result should change, and when to retest.
Does AMORTAL order the test for me?
No. AMORTAL is not a lab marketplace and does not order or sell tests. It works from results you already have — from Mito, a clinician, or any other lab. If a decision genuinely needs a marker you haven't booked yet, AMORTAL will say so and tell you which one would actually change the decision, rather than encouraging you to book a slice of a 1,000-plus menu.
What does AMORTAL do after my Mito results come in?
It files them into your health memory, activates the standards that apply to you, and produces a Decision Contract: one next best action, the single signal you'd expect it to move, and the window to watch. It also creates watchlist items for markers worth re-checking later — and, importantly, will tell you when the right move is to change nothing yet.
Is a bigger marker menu always better?
Not automatically. A 1,000-plus menu like Mito's is genuinely useful for access, but more markers also mean more borderline results that tempt over-reaction. AMORTAL evaluates whether a marker actually changes a realistic decision, whether the result is timely, whether a clinician should weigh in, and what downstream signal to watch — so breadth becomes useful instead of noisy.
Mito lets me browse 1,000+ markers — how do I not over-test?
A huge menu is great for access, but it also invites over-testing — it's easy to add every slightly-curious marker to the cart. AMORTAL works the other way: before you book, it evaluates whether a marker would change a realistic decision, whether you already have a recent value, and what you'd actually do with the answer. That turns a 1,000-plus menu into a short, useful list — and tells you which markers to leave on the shelf.